Studies confirm regorafenib benefit in pre-treated metastatic colorectal cancer

3 julio 2015

The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers. The safety profile and progression free survival were similar to phase III trial results.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/saXZVP2Cyz8/150703072607.htm

Volver